Atherosclerosis research has long focused on lipid accumulation and macrophage activity, but the immune architecture within arterial plaques is far more intricate. A mechanistic pathway linking a rare regulatory T-cell subset to the behavior of the smooth muscle cells that physically stabilize or destabilize plaques could reframe how cardiovascular immunotherapy is approached — and potentially shift targets from LDL alone toward immune modulation.
Using single-cell RNA sequencing of human atherosclerotic tissue combined with multiple mouse models, this study identifies CD8+ T cells as the dominant immune cell type communicating directly with vascular smooth muscle cells (VSMCs) in arterial plaques, doing so via the CD8α receptor. When conventional CD8+ T cells localize to the arterial media, they suppress VSMC Notch signaling — a pathway the researchers show is genuinely protective. Genetic ablation of Notch in smooth muscle cells accelerated plaque formation in Apoe-deficient mice, accompanied by heightened VSMC proliferation, inflammatory signaling, and phenotypic switching away from a contractile state. Critically, blocking CD8α with non-depleting antibodies induced a CD8+CD44+CD122+ regulatory T-cell population that reversed this dynamic: these Tregs activated VSMC Notch partly through IL-10, restoring a more stable smooth muscle phenotype and limiting lesion progression.
This work is mechanistically ambitious, integrating human genomic data, adoptive transfer experiments, lineage tracing, and ChIP-seq to map a complete immune-to-VSMC regulatory axis. The IL-10/Notch connection is particularly notable because both pathways are druggable. However, the findings rely heavily on mouse atherosclerosis models, which imperfectly recapitulate human disease progression and plaque vulnerability. The CD8+CD44+CD122+ Treg population is understudied in cardiovascular contexts, and whether it can be safely expanded or induced in humans without immunosuppressive side effects remains an open question. That said, framing VSMC Notch signaling as a downstream effector of immune regulation — rather than purely an intrinsic cellular program — represents a genuinely novel conceptual contribution that warrants attention from the cardiovascular biology community.